News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 Great news!  This brings the vaccine closer to approval. Early reports showed over a 6 month improvement in survival, which is significant and 23% of patients had tumor reductions.  Fast track designation and orphan designation mean the FDA has looked at the data and shows an interest in speeding it up.  


Posted on: 06/15/2020

Cancer Vaccine Plus Adoptive T-cell Therapy Placed on Fast Track

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740